Back to Search
Start Over
Anti-EGFR Monoclonal Antibodies in Advanced Biliary Tract Cancer: A Systematic Review and Meta-analysis.
- Source :
-
In vivo (Athens, Greece) [In Vivo] 2020 Mar-Apr; Vol. 34 (2), pp. 479-488. - Publication Year :
- 2020
-
Abstract
- Background: Despite several clinical trials and advances in understanding the genetic basis of biliary tract cancer (BTC), the addition of epidermal growth factor receptor (EGFR) targeted therapy does not seem to enhance the activity of first-line chemotherapy (CHT).<br />Materials and Methods: We carried out a meta-analysis of available randomized clinical trials to assess the efficacy and safety of gemcitabine-based first-line CHT plus monoclonal antibodies against EGFR (EGFR-mAbs) in advanced or metastatic BTC.<br />Results: In the overall population, the pooled hazard ratio for overall (OS) and progression-free (PFS) survival were 0.82 (95% confidence interval=0.64-1.06) and 0.88 (95% confidence intervaI=0.73-1.08), respectively. No differences were detected in objective response rate between the two groups. Patients treated with gemcitabine-based CHT plus EGFR-mAbs showed a statistically significant increased risk of grade 3-4 neutropenia, grade 3-4 thrombocytopenia and especially grade 3-4 skin rash.<br />Conclusion: The addition of EGFR-mAbs to gemcitabine-based first-line CHT does not significantly improve overall and progression-free survival, nor the objective response rate in patients with advanced BTC and increases the risk of hematological and cutaneous adverse drug events.<br /> (Copyright© 2020, International Institute of Anticancer Research (Dr. George J. Delinasios), All rights reserved.)
- Subjects :
- Antibodies, Monoclonal administration & dosage
Antibodies, Monoclonal adverse effects
Antineoplastic Agents, Immunological administration & dosage
Antineoplastic Agents, Immunological adverse effects
Antineoplastic Combined Chemotherapy Protocols adverse effects
Antineoplastic Combined Chemotherapy Protocols therapeutic use
Bile Duct Neoplasms etiology
Bile Duct Neoplasms mortality
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
ErbB Receptors antagonists & inhibitors
Humans
Molecular Targeted Therapy
Neoplasm Staging
Odds Ratio
Randomized Controlled Trials as Topic
Treatment Outcome
Antibodies, Monoclonal therapeutic use
Antineoplastic Agents, Immunological therapeutic use
Bile Duct Neoplasms drug therapy
Bile Duct Neoplasms pathology
Subjects
Details
- Language :
- English
- ISSN :
- 1791-7549
- Volume :
- 34
- Issue :
- 2
- Database :
- MEDLINE
- Journal :
- In vivo (Athens, Greece)
- Publication Type :
- Academic Journal
- Accession number :
- 32111744
- Full Text :
- https://doi.org/10.21873/invivo.11798